Oncology Expertise that Fuels Your Development Success

 
                                                 
                                                 
                                                 
                                                 
                                                 
                                                 
                                         
                                         
                                         
                                     
                                    
 
                                                                 
                                                                 
                                                                 
                                                                 
                                                                 
                                                                 
                                                                 
                                             
                                             
                                             
                                                 
                                            Published in Contract Pharma September 2022
With more than $185 billion in global investment in research and development, global oncology drug development is leading the way in clinical trial activity and in the launch of novel medicines. In addition to the emphasis on survival, stakeholders are focused on improving the current quality of life for patients and strengthening the overall cancer care paradigm. In this article, read about the latest in CAR-T therapies, dose optimization in early phase oncology trials, and operational considerations for clinical trials.
Contact us to connect your oncology program with solutions to support your success.
Oncology Expertise that Fuels Your Development Success
Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.